Precision’s Allo CAR-T Inches Closer To Filling Post-Auto CAR-T Niche

 
• By Alaric DeArment
  
Precision BioSciences announced Phase I/IIa data for its allogeneic CAR-T therapy • Source: Shutterstock

More from Immuno-oncology

More from Anticancer